A Rare Disease With Diverse Manifestations

This mini-review deals with a new appraisal of cerebrotendinous xanthomatosis. In addition to neurologic symptoms, patients with cerebrotendinous xanthomatosis develop cataracts, diarrhea, Achilles tendon xanthoma, atherosclerotic vascular disease, and many other abnormalities. Although the pathophysiology of the disease is not completely understood, excess production and consequent accumulation of cholestanol in tissues may play a crucial role. Chenodeoxycholic acid is the most effective therapy. The causative role and detrimental effects (at a low plasma level) of cholestanol merit further investigation. Arch Neurol. 2002;59:527-529 Cerebrotendinous xanthomatosis (CTX) is anautosomalrecessivediseasecharacterized by formation of xanthomatous lesions in many tissues, in particular the brain and tendons. The diagnosis of CTX before neurologic deterioration is crucial to prevent brain damage that leads to severe mental and neurologicdysfunctionanddeath.Inthisregard, specific biochemical abnormalities include elevated plasma and bile cholestanol levels and increased urinary excretion of bile alcohol glucuronides associated with diminished biliary concentrations of chenodeoxycholic acid. In children unexplained bilateral cataracts with chronic diarrhea are the features that suggest this diagnosis before the onset of neurologic disease. Cerebrotendinous xanthomatosis is potentially treatable with improvement in neurologic function. Replacement therapy with chenodeoxycholic acid inhibits abnormal bile acid synthesis and is most effective in reducing elevated plasma cholestanol concentrations, and eliminating bile alcohols.

[1]  A. Hofman,et al.  Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[2]  H. Segev,et al.  Premature termination codon at the sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in a French family , 1995, Human Genetics.

[3]  Y. Tokimura,et al.  Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use , 1994, Journal of the Neurological Sciences.

[4]  A. Federico,et al.  Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism , 1993, Journal of the Neurological Sciences.

[5]  U. Francke,et al.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. , 1991, The Journal of biological chemistry.

[6]  G. Ness,et al.  A molecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis. , 1990, The Journal of clinical investigation.

[7]  N. Le,et al.  Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis. , 1989, Journal of lipid research.

[8]  A. Quyyumi,et al.  Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. , 1988, The American journal of cardiology.

[9]  B. G. Wolthers,et al.  Cerebrotendinous xanthomatosis: A review of biochemical findings of the patient population in the netherlands , 1988, Journal of Inherited Metabolic Disease.

[10]  G. Tint,et al.  Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. , 1987, The New England journal of medicine.

[11]  S. Shefer,et al.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. , 1984, The New England journal of medicine.

[12]  G. Tint,et al.  Transformation of 4-cholesten-3-one and 7α-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis , 1984 .

[13]  S. Grundy,et al.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis. , 1973, The Journal of clinical investigation.

[14]  G. Salen Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism. , 1971, Annals of internal medicine.